Neogenomics (NEO) Retained Earnings (2010 - 2026)

Neogenomics (NEO) has 17 years of Retained Earnings data on file, last reported at -$448.7 million in Q2 2026.

• Quarterly Retained Earnings fell 13.07% year-over-year to -$448.7 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was -$448.7 million (down 13.07% YoY) and the FY2025 annual result came in at -$433.8 million, down 33.16% from the prior year.
• Retained Earnings steadied at -$448.7 million in Q2 2026, from -$450.9 million in the prior quarter.
• In the past five years, Retained Earnings ranged from a high of -$64.2 million in Q1 2022 to a low of -$450.9 million in Q1 2026.
• A 5-year average of -$280.7 million and a median of -$283.4 million in 2024 frame the typical range for Retained Earnings.
• Annual changes were most pronounced in 2022 — Retained Earnings tumbled 972.23% — and 2026, when it retreated 13.07%.
• Tracing NEO's Retained Earnings over 5 years: stood at -$159.1 million in 2022, then tumbled by 55.3% to -$247.1 million in 2023, then slumped by 31.87% to -$325.8 million in 2024, then plunged by 33.16% to -$433.8 million in 2025, then fell by 3.43% to -$448.7 million in 2026.
• The last three Retained Earnings figures came in at -$448.7 million (Q2 2026), -$450.9 million (Q1 2026), and -$433.8 million (Q4 2025), per Business Quant data.